Phase i and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma

Hidefumi Wada, Ryoji Tsuboi, Yukihiko Kato, Makoto Sugaya, Kensei Tobinai, Toshihisa Hamada, Takashi Shimamoto, Kazuo Noguchi, Keiji Iwatsuki

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

A phase I study was conducted to evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of the oral histone deacetylase (HDAC) inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Six patients received vorinostat (400 mg p.o., once daily). Dose-limiting toxicities (DLT) were evaluated in all six patients during the 28 days of the first cycle. One of the six patients who received vorinostat developed a DLT (grade 4 thrombocytopenia). The most common drug-related adverse events included nausea (4/6, 67%), thrombocytopenia (4/6, 67%), hyperbilirubinemia (3/6, 50%) and vomiting (3/6, 50%). Most of these events were reversible and were resolved by supportive care and/or the interruption of vorinostat treatment. The safety and PK profiles of vorinostat in Japanese patients with CTCL did not appear to differ from those previously observed in non-Japanese and Japanese patients with advanced solid tumors. None of the patients achieved an objective response in this study. However, one unconfirmed partial response and two cases of sustained stable disease for 12 weeks or longer were observed among the six patients in the study. One of the three evaluable patients experienced pruritus relief. Vorinostat was well tolerated at a dose of 400 mg p.o. once daily and showed potential efficacy in Japanese patients with CTCL, warranting further investigation.

Original languageEnglish
Pages (from-to)823-828
Number of pages6
JournalJournal of Dermatology
Volume39
Issue number10
DOIs
Publication statusPublished - Oct 2012

Fingerprint

Cutaneous T-Cell Lymphoma
Histone Deacetylase Inhibitors
Pharmacokinetics
vorinostat
Safety
Hyperbilirubinemia
Pruritus
Drug-Related Side Effects and Adverse Reactions
Nausea
Vomiting

Keywords

  • cutaneous T-cell lymphoma
  • histone deacetylase inhibitor
  • mycosis fungoides
  • pruritus relief
  • vorinostat

ASJC Scopus subject areas

  • Dermatology

Cite this

Phase i and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma. / Wada, Hidefumi; Tsuboi, Ryoji; Kato, Yukihiko; Sugaya, Makoto; Tobinai, Kensei; Hamada, Toshihisa; Shimamoto, Takashi; Noguchi, Kazuo; Iwatsuki, Keiji.

In: Journal of Dermatology, Vol. 39, No. 10, 10.2012, p. 823-828.

Research output: Contribution to journalArticle

Wada, Hidefumi ; Tsuboi, Ryoji ; Kato, Yukihiko ; Sugaya, Makoto ; Tobinai, Kensei ; Hamada, Toshihisa ; Shimamoto, Takashi ; Noguchi, Kazuo ; Iwatsuki, Keiji. / Phase i and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma. In: Journal of Dermatology. 2012 ; Vol. 39, No. 10. pp. 823-828.
@article{0947eccf14a741e8942d81dc6c50a7dc,
title = "Phase i and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma",
abstract = "A phase I study was conducted to evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of the oral histone deacetylase (HDAC) inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Six patients received vorinostat (400 mg p.o., once daily). Dose-limiting toxicities (DLT) were evaluated in all six patients during the 28 days of the first cycle. One of the six patients who received vorinostat developed a DLT (grade 4 thrombocytopenia). The most common drug-related adverse events included nausea (4/6, 67{\%}), thrombocytopenia (4/6, 67{\%}), hyperbilirubinemia (3/6, 50{\%}) and vomiting (3/6, 50{\%}). Most of these events were reversible and were resolved by supportive care and/or the interruption of vorinostat treatment. The safety and PK profiles of vorinostat in Japanese patients with CTCL did not appear to differ from those previously observed in non-Japanese and Japanese patients with advanced solid tumors. None of the patients achieved an objective response in this study. However, one unconfirmed partial response and two cases of sustained stable disease for 12 weeks or longer were observed among the six patients in the study. One of the three evaluable patients experienced pruritus relief. Vorinostat was well tolerated at a dose of 400 mg p.o. once daily and showed potential efficacy in Japanese patients with CTCL, warranting further investigation.",
keywords = "cutaneous T-cell lymphoma, histone deacetylase inhibitor, mycosis fungoides, pruritus relief, vorinostat",
author = "Hidefumi Wada and Ryoji Tsuboi and Yukihiko Kato and Makoto Sugaya and Kensei Tobinai and Toshihisa Hamada and Takashi Shimamoto and Kazuo Noguchi and Keiji Iwatsuki",
year = "2012",
month = "10",
doi = "10.1111/j.1346-8138.2012.01554.x",
language = "English",
volume = "39",
pages = "823--828",
journal = "Journal of Dermatology",
issn = "0385-2407",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Phase i and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma

AU - Wada, Hidefumi

AU - Tsuboi, Ryoji

AU - Kato, Yukihiko

AU - Sugaya, Makoto

AU - Tobinai, Kensei

AU - Hamada, Toshihisa

AU - Shimamoto, Takashi

AU - Noguchi, Kazuo

AU - Iwatsuki, Keiji

PY - 2012/10

Y1 - 2012/10

N2 - A phase I study was conducted to evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of the oral histone deacetylase (HDAC) inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Six patients received vorinostat (400 mg p.o., once daily). Dose-limiting toxicities (DLT) were evaluated in all six patients during the 28 days of the first cycle. One of the six patients who received vorinostat developed a DLT (grade 4 thrombocytopenia). The most common drug-related adverse events included nausea (4/6, 67%), thrombocytopenia (4/6, 67%), hyperbilirubinemia (3/6, 50%) and vomiting (3/6, 50%). Most of these events were reversible and were resolved by supportive care and/or the interruption of vorinostat treatment. The safety and PK profiles of vorinostat in Japanese patients with CTCL did not appear to differ from those previously observed in non-Japanese and Japanese patients with advanced solid tumors. None of the patients achieved an objective response in this study. However, one unconfirmed partial response and two cases of sustained stable disease for 12 weeks or longer were observed among the six patients in the study. One of the three evaluable patients experienced pruritus relief. Vorinostat was well tolerated at a dose of 400 mg p.o. once daily and showed potential efficacy in Japanese patients with CTCL, warranting further investigation.

AB - A phase I study was conducted to evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of the oral histone deacetylase (HDAC) inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Six patients received vorinostat (400 mg p.o., once daily). Dose-limiting toxicities (DLT) were evaluated in all six patients during the 28 days of the first cycle. One of the six patients who received vorinostat developed a DLT (grade 4 thrombocytopenia). The most common drug-related adverse events included nausea (4/6, 67%), thrombocytopenia (4/6, 67%), hyperbilirubinemia (3/6, 50%) and vomiting (3/6, 50%). Most of these events were reversible and were resolved by supportive care and/or the interruption of vorinostat treatment. The safety and PK profiles of vorinostat in Japanese patients with CTCL did not appear to differ from those previously observed in non-Japanese and Japanese patients with advanced solid tumors. None of the patients achieved an objective response in this study. However, one unconfirmed partial response and two cases of sustained stable disease for 12 weeks or longer were observed among the six patients in the study. One of the three evaluable patients experienced pruritus relief. Vorinostat was well tolerated at a dose of 400 mg p.o. once daily and showed potential efficacy in Japanese patients with CTCL, warranting further investigation.

KW - cutaneous T-cell lymphoma

KW - histone deacetylase inhibitor

KW - mycosis fungoides

KW - pruritus relief

KW - vorinostat

UR - http://www.scopus.com/inward/record.url?scp=84867103267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867103267&partnerID=8YFLogxK

U2 - 10.1111/j.1346-8138.2012.01554.x

DO - 10.1111/j.1346-8138.2012.01554.x

M3 - Article

C2 - 22506596

AN - SCOPUS:84867103267

VL - 39

SP - 823

EP - 828

JO - Journal of Dermatology

JF - Journal of Dermatology

SN - 0385-2407

IS - 10

ER -